1. Leavitt, B. R. & Hayden, M. R. in Kelley's Textbook of Internal Medicine. 4th ed. (Lippincott, Williams and Wilkins, Philadelphia, 2000).
2. Landles, C. & Bates, G. P. Huntingtin and the molecular pathogenesis of Huntington's disease. EMBO Rep. 5, 958–963 (2004).
3. Graham, R. K. et al. Cleavage at the caspase 6 site in huntingtin is required for motor dysfunction, neurodegeneration and excitotoxicity in Huntington Disease. Cell 125, 1179–1191 (2006).
4. Grimbergen, Y. A. & Roos, R. A. Therapeutic options for Huntington's disease. Curr. Opin. Invest. Drugs 4, 51–54 (2003).
5. Quinn, G. P., Shore, P. A. & Brodie, B. B. Biochemical and pharmacological studies of RO1-9569 (tetrabenazine), a non-indole tranquilizing agent with reserpine-like effects. J. Pharmacol. Exp. Ther. 127, 103–109 (1959).